Ep90: James Sabry on Partnering Amid Scientific Abundance

Episode Summary

Executive Summary: James Sabry argues that biotech has entered a rare period where capital and technological innovation are rising together, enabling new modalities like gene therapy, RNA-targeted drugs, cell therapy, and degraders. He explains how Roche/Genentech evolved from a mostly internal discovery culture to a more open, collaborative, long-term partnering model embedded in R&D, and why patience, trust, and global integration are essential to building future medicines.

Main Topics: Biotech’s shift from transactional deals to relationship-driven partnering (Priority: 5/5): Sabry emphasizes that chance meetings, trust, and long-term relationships are central to biotech business development, especially in a small industry where talent, investors, and pharma leaders repeatedly cross paths. Genentech/Roche culture and organizational integration (Priority: 5/5): He describes how Genentech retained its entrepreneurial culture after Roche’s acquisition and how business development was deliberately embedded inside R&D, eventually leading to a single global partnering group across Basel and South San Francisco. Capital cycles versus technology cycles in biotech (Priority: 5/5): Sabry contrasts funding waves with scientific waves, arguing that the 2010s uniquely aligned abundant capital with a wave of real modality innovation, producing an unusually fertile environment for biotech. Long-term investment in new modalities (Priority: 5/5): He argues that Roche must keep expanding beyond traditional antibodies and small molecules into gene therapy, cell therapy, RNA-targeted chemistry, bispecifics, and degraders to stay relevant over decades. Deal-making strategy across early and late stages (Priority: 4/5): Sabry outlines a mixed approach: large early-stage collaborations that provide non-dilutive capital and operational support, plus selective late-stage deals when strategically compelling. Which areas are promising or overhyped (Priority: 4/5): He is most bullish on gene therapy as a future mainstay, cautious on cell therapy for solid tumors, and skeptical about near-term transformational therapies in neurodegeneration due to scientific immaturity. Leadership, reading, and long-term thinking (Priority: 3/5): Sabry closes by urging leaders to protect time for reading and reflection, arguing that thoughtful solitude is necessary to develop independent judgment rather than merely echoing others.

Key Arguments: Biotech is a small ecosystem, so trust-building interactions at conferences matter because they accelerate future collaborations. Business development should be treated as part of R&D, not a separate transactional function, so external innovation can fit the internal strategy. The 2010s created an unprecedented alignment of scientific modality breakthroughs and abundant capital, fueling major progress. A company that only pursues its historical strengths risks becoming irrelevant; Roche/Genentech must keep adopting new modalities. Gene therapy is likely to become a major therapeutic pillar because it can address root genetic causes in a potentially one-time treatment. Long-term ownership structure at Roche supports investments that may not pay off for 20–40 years but can define the company’s future. Large early-stage partnerships can be attractive because they provide non-dilutive capital and let biotech partners focus on science instead of constant fundraising. Despite stronger biotech funding, pharma partnerships remain necessary because startups often lack the operational scale to develop and commercialize drugs alone. Cell therapy has not yet solved solid tumors, so high valuations in that sector can outpace technological readiness. Neurodegenerative disease drug development remains immature scientifically, making near-term transformative success less likely.

Data Points: Genentech partnering team size at arrival: 15 to 20 people - Size of the Genentech partnering group when Sabry joined in 2010 Genentech full employee count mentioned: 15,000 employees - Used to illustrate that Genentech still felt nimble and entrepreneurial despite its size Roche/Genentech integration timing: March 2009 - Roche fully took over Genentech before Sabry joined Time from Roche takeover to Sabry’s arrival: about 8 months - He joined roughly eight months after the full acquisition Sabry’s time at Genentech before global role: about 12 years - He had worked at Genentech for roughly 12 years before taking a broader Roche role Global partnering reorganization: 2 years ago - The Roche and Genentech partnering groups were combined into one global organization two years prior to the interview Roche R&D spending: over $12 billion in 2020 - Cited to show the scale of Roche’s research engine Partnership agreements in 2018: 107 agreements - Number of acquire/license/collaborate agreements cited from Roche/Genentech websites Spark acquisition price: $5.1 billion - Referenced as an example of a long-term gene therapy investment Time horizon for long-term value creation: 30 to 40 years - Sabry’s preferred planning horizon for major healthcare company relevance Arrival of biotech capital inflow phase: starting around 2014–2015 - Sabry says biotech funding began flowing back strongly then Capital environment in 2010: limited capital / buyer’s market - Early period of his Genentech role when startups were stressed for funding Typical deal timing for Genentech in-licenses: preclinical or very early clinical - Most in-licensed programs are brought in very early rather than near market Late-stage deals mentioned: Sarepta, Atea, Regeneron, Blueprint Medicines - Examples of the variety of partnership stages Roche pursues

Pivotal Quotes: "Biotech still is a small industry where you can know a large percentage of the entrepreneurs, of the investors, of the people in the pharmaceutical industry." — James Sabry: Explaining why in-person conference interactions and trust matter so much in biotech partnering "If Genentech and Roche only discover and develop monoclonal antibodies and small molecules, within a number of decades, we will be an unimportant company." — James Sabry: Arguing that Roche must embrace new modalities to remain strategically important "Gene therapy, in my opinion, will become, in the long run, one of the major mainstays of treating disease." — James Sabry: Describing his strongest long-term scientific conviction

Implications: For biotech and pharma leaders, the message is to pair scientific openness with long-term capital discipline: build partnerships early, stay close to frontier modalities, and invest patiently in technologies that may define medicine decades from now.